Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:MYO
CUSIPN/A
Phone+1-617-9969058
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-257.70%
Return on Equity-155.42%
Return on Assets-73.21%
Miscellaneous
EmployeesN/A
Outstanding Shares12,410,000
Market Cap$24.74
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) issued its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The company earned $0.31 million during the quarter, compared to analyst estimates of $0.56 million. Myomo had a negative return on equity of 155.42% and a negative net margin of 257.70%. View Myomo's Earnings History.
What price target have analysts set for MYO?
2 Wall Street analysts have issued twelve-month target prices for Myomo's stock. Their forecasts range from $7.00 to $12.00. On average, they expect Myomo's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 278.5% from the stock's current price. View Analyst Ratings for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Myomo?
Myomo saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 957,293 shares, a decrease of 7.5% from the June 15th total of 1,035,027 shares. Based on an average daily trading volume, of 159,383 shares, the days-to-cover ratio is currently 6.0 days. Approximately 9.2% of the company's shares are short sold. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Creo Medical Group (CREO), Hamilton Thorne (HTL), Kromek Group (KMK), Electromed (ELMD), Universal Biosensors (UBI), Advanced Oncotherapy (AVO), Protech Home Medical (PHM), MRI Interventions (MRIC), Surgical Innovations Group (SUN), Neuroone Medical Technologies (NMTC), PetVivo (PETV), Avacta Group (AVCT), GI Dynamics (GID), Airware Labs (AIRW) and Inspiration Healthcare Group (IHC).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)
- Mr. Jonathan Naft, VP & GM (Age 53)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68)
Has Myomo been receiving favorable news coverage?
Press coverage about MYO stock has been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Myomo earned a media sentiment score of 0.09 on Accern's scale. They also gave news articles about the company an impact score of 46.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Myomo's major shareholders?
Which institutional investors are buying Myomo stock?
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $2.51.
How big of a company is Myomo?
Myomo has a market capitalization of $24.74 million.
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
